International Journal of Endocrinology / 2012 / Article / Tab 3

Review Article

Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials

Table 3

Overview of the included randomized, placebo-controlled studies with alpha lipoic acid in persons with symptomatic peripheral diabetic neuropathy.

Study
1st author, year; study name
Research groupLength of studyAlpha lipoic acid dosageAdministration routePrimary outcome measureFindingsDifference intervention versus control* (Significance)level of evidence
Patient typeNumber of patients (Intervention/control)InterventionControl

Ziegler 1995 ALADIN [15]DM2; 18–70 yr328 (65/63/66/66)3 weeks(a) 100 mg daily
(b) 600 mg daily
(c) 1200 mg daily
IntravenousTSS(a) 7.6 → 4.3
(b) 7.8 → 2.8
(c) 7.6 → 3.1
6.8 → 4.2−0.7 (ns)
−2.4
−1.9
1b
Ruhnau 1999 ORPIL [16]DM2; 18–70 yr24 (12/12)3 weeks3dd600 mgOralTSS7.99 → 4.248.18 → 6.24−1.81 1b
Ametov 2003 SYDNEY [17]DM1+ DM2; 18–74 yr120 (60/60)3 weeks600 mg daily for 14 daysIntravenousTSS−5.72−1.83−3.89 1b
Ziegler 2006 SYDNEY 2 [18]DM1+ DM2; 18–74 yr181 (45/47/46 /43)5 weeks(a) 600 mg daily
(b) 1200 mg daily
(c) 1800 mg daily
OralTSS(a) 9.44 → 4.59
(b) 9.40 → 4.90
(c) 9.02 → 4.32
9.27 → 6.35−1.93
−1.58
−1.78
1b

*Calculated differences between intervention and control groups: not controlled.
DM: diabetes mellitus.
ns: not significant.
TSS: Total Symptom Score.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.